Naturopathic Women's Health Conference - All PresentationsOriginal Date: March 19-20, 2022This discounted package includes all of the individual presentations from the conference, which are listed below.12.0 CEUs (including 7.75 general, 3.0 pharmacy, 0.75 ethics, and 0.5 cultural competency) approved by OBNM
Women’s Health Research Update - What’s New, What’s In, What’s Out, What WorksPresenter: Tori Hudson, NDOriginal Date: March 19, 2022A steady stream of research on diet, individual nutrients and botanicals provides vital and relevant information for clinicians in everyday practice who are treating women for the plethora of primary care and/or gynecological issues they face. Staying up to date on this research can be challenging and even daunting. This lecture will highlight research from 2018 to early 2022, and studies that can make a difference in the results and outcomes for your patients.... and a few that don’t.1.5 CEUs (including 1.25 general and 0.25 ethics)approved by OBNM
Your Body on the Pill - Supporting PatientsPresenter: Jolene Brighten, NDOriginal Date: March 19, 2022While the pill was designed primarily to prevent pregnancy and elicit its effect on the HPQ axis, it has far reached systematic effects. The impact on mood, gut health, and cardiometabolic heath is a topic in which all prescribers should be informed. We will discuss the key systems the pill can affect, how to evaluate and screen for who is at risk and considerations for postpartum. We will also discuss how to safely support your patient in their choice to use this form of birth control.1.5 CEUs (including 1.0 general, 0.25 pharm, and 0.25 ethics)approved by OBNM
Supporting Breast Cancer Patients with Naturopathic MedicinePresenter: Kimberly Windstar, ND, MEdOriginal Date: March 19, 2022-Breast Cancer epidemiology and modifiable risk factors-Supporting breast cancer patients with naturopathic medicine-Lifestyle recommendations-Alcohol, smoking, diet, exercise, stress management-Mind/body and mindfulness-Choices around therapies-Complimenting Radiation and Chemotherapy-Complimenting recovery1.5 CEUs (including 1.25 general and 0.25 pharm)approved by OBNM
Preconception Care: Updated Recommendations and How to Implement Seamlessly into Your PracticePresenter: Haylee Nye, NDOriginal Date: March 19, 2022The goal of preconception care is to reduce the short-term and long-term risk of health effects during pregnancy and beyond for the mother and baby. Also known as “pre-pregnancy counseling”, it involves optimizing health, addressing modifiable risk factors, and providing education for the couple. Guidelines for this visit were established by ASRM and ACOG in 2019. This presentation will go over these guidelines and how to implement into practice. This includes identifying and addressing important medical concerns of the couple, reviewing medications and supplements, addressing lifestyle factors such as alcohol intake, expanded carrier screening, and lab screening.1.5 CEUs (including 1.0 general, 0.25 pharm, and 0.25 ethics)approved by OBNM
Hair Loss in Women: Updates in Diagnosis and TreatmentPresenter: Julie Greenberg, NDOriginal Date: March 20, 2022Sex-related differences in anatomy and physiology mean that female patients can face different hair loss issues than male patients. This presentation will focus on hair conditions that disproportionately affect female patients including: female pattern baldness, telogen effluvium, frontal fibrosing alopecia, traction alopecia and many more. We will discuss the latest research on the pathophysiology of these diseases, as well as both pharmaceutical and evidence-based alternative approaches to treatment.1.5 CEUs (including 0.5 general, 0.75 pharm, and 0.25 cultural competency)approved by OBNM
Testosterone: Uses in Women’s Health and in Gender DiversityPresenter: Suzanne Scopes, NDOriginal Date: March 20, 2022● Testosterone physiology and pharmacokinetics● Testosterone therapy• Safety and efficacy of testosterone therapy for perimenopausal and menopausal cis women• Lab and RX as connected● Understanding gender diversity and inclusive language● Indications for testosterone across the genderspectrum (For non-binary and transmasculinepeople)● Safety of testosterone in usual doses for transgender men● Testosterone therapy dosing across spectrum1.5 CEUs (including 0.75 general, 0.5 pharm, and 0.25 cultural competency)approved by OBNM
The Menopausal Metabolic Transition: How Metabolic Flexibility Eases Crossing the Perimenopausal BridgePresenter: Bonnie Nedrow, NDOriginal Date: March 20, 2022This presentation will assist the clinician in addressing metabolic diseases commonly encountered in menopausalwomen including overweight, obesity, heart disease, diabetes and fatty liver. The interactions between metabolismand hormones will be described and a therapeutic approach that includes lifestyle interventions, herbs,nutraceuticals and motivational strategies will be presented. The role of obesogenic chemicals, the risks of rapidweight loss and the importance of detoxification during any weight-loss program will be defined with clinical toolsoffered to support efficacy and safety of metabolic rebalancing.1.5 CEUs (including 1.0 general and 0.5 pharm)approved by OBNM
Gynecological CancersPresenter: Cynthia Bye, ND and Charissa Bausch, NDOriginal Date: March 20, 20221. Variety of Gynecological cancers2. Possible factors of causation3. Choices of care- overview of phases of care4. Co-management during standard of Care and drugs relevant and possible responses: Nausea, Pancytopenia,Neuropathy, Cardiotoxicity, Hepatotoxicityi. Specific Issues relevant to Gynecological Cancers1. Complexities of reproduction and reproduction seasons and age cycles5. Remission retention/survivorship/long term care,i. Address causative factors and long-term side effects of treatment1. Common causative factors/drivers2. Side effectsii. Modulation of carcinogenic drivers.1. No Evidence of disease2. Those that still have cancer after standard of careiii. Other lifestyle concerns and issues.Pharma covered Alkeran (Melphalan),Avastin Bevacizumab)Bevacizumab, Carboplatin Cisplatin, Cyclophosphamide, DoxorubicinHydrochloride, Doxil (Doxorubicin Hydrochloride Liposome, Doxorubicin Hydrochloride Liposome, Gemcitabine Hydrochloride,Hycamtin (Topotecan Hydrochloride), Infugem (Gemcitabine Hydrochloride), Lynparza (Olaparib), Melphalan, NiraparibTosylate,Monohydrate, Olaparib, Paclitaxel, Paraplatin (Carboplatin), Rubraca (Rucaparib Camsylate, Rucaparib Camsylate, Tepadina(Thiotepa), ThiotepaTopotecan Hydrochloride, Zejula (Niraparib Tosylate Monohydrate)1.5 CEUs (including 1.0 general and 0.5 pharm) approved by OBNM
